The Orphan Drug Designation (ODD), a legislative and regulatory framework, provides a number of incentives supporting companies developing drugs for rare diseases. This framework has been adopted by a number of countries and regions, including the EU, US, and Japan. Although there are similarities among these regions, criteria and procedures vary.
We can support you with:
Application for ODD in the EU, US, and Japan
Activities after ODD